According to the warning letter, Purolea used AI agents to generate drug product specifications, standard operating procedures and master production and control records, with the stated aim of supporting FDA compliance
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
Ozempic, Wegovy, Zepbound), estimated copay and/or out-of-pocket costs, the latest drug supply data, and information about options available through Ro
Loeber, G., Dworkin, M
Publishers Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations